Determining the type of diabetes a patient has at diagnosis can be challenging, and health care professionals should focus on each patient’s clinical condition when determining initial treatment, ...

Healthcare stocks can provide growth and consistent returns through a variety of market cycles. Eli Lilly has a storied ...

American pharmaceutical giant Eli Lilly is investing 3 billion dollars (roughly 2.6 billion euros) to build a new factory in Katwijk. The project is expected to create 500 permanent manufacturing jobs ...

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless”.

Tirzepatide, a medication sold under the names Mounjaro for diabetes and Zepbound for weight loss, has shown impressive results in helping people avoid developing diabetes. A new study found that it ...

The U.S. stock market sank from record heights as Wall Street sifted through mixed developments on everything from the ...

Biotech Viking Therapeutics has gained prominence over the past two years, but it could have plenty of upside left.

Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.

These growth stocks are highly profitable and evolving in their respective industries. Eli Lilly is famed for its weight-loss medications, but it is more than just a GLP-1 play. MercadoLibre is a ...

Eli Lilly delivered a stunning financial performance that exceeded even the most optimistic market expectations, driven by unprecedented demand for its ...

El ensayo clínico, que busca reclutar a 1000 pacientes con COVID persistente en todo el país, explorará cómo la autoadministración de tirzepatida, el agonista del GLP-1 de Eli Lilly comercializado ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.